Accent Microcell Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹1,521 Cr
- P/E
- 26.73
- ROE
- 18.65%
- PEG
- 0.50
- Price to sales
- 3.95
- Debt to equity
- 0.00
- 52W high / low
- ₹726 / ₹266
- Sales growth (5Y)
- 21.36%
- EBITDA margin
- 19.28%
- Net profit margin
- 12.57%
- Promoter holding
- 51.40%
- Sales (last year)
- ₹385 Cr
Incorporated in 2012, Accent Microcell Ltd manufactures Pharmaceutical Excipients[1]
Guidance scorecard · Q2 FY27 call
What Accent Microcell's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ4 FY26 call
10–20%- FY27 growth expected primarily from Phase 1 of Unit 3 and premium excipient product range launched in H2 FY26.
- Phase 2 of Unit 3 expected to go commercial by March 2027, adding further manufacturing revenue.
- Trading volumes currently elevated to retain customer base; expected to reduce once Phase 1 and Phase 2 capacities fully utilized.
- Revenue from Phase 1 anticipated around ₹340-350 crore by end of FY27 but not at peak capacity in first year.
- Export revenue share likely to increase due to premium products and MCC Spheres production targeting global markets.
- Gradual increase in premium product revenue share expected, reaching ~16-17% in FY27 from 13% in FY26.
2 more points from Accent Microcell's call on revenue
Create a free account to keep reading this call
MarginsQ4 FY26 call
Up 2%+See what Accent Microcell said on margins — free account, 30 seconds.
CapexQ4 FY26 call
Planned- Future phases planned up to Phase 6, with internal accruals expected to fund expansion without outside debt.
- Right issue and internal cash flows are funding Phase 1 and Phase 2; no new debt planned currently.
- Working capital and term loan limits with Kotak Mahindra Bank are available if needed, but no immediate borrowing plans.
- MCC Spheres capacity is about 100 tons per month, with gradual ramp-up aligned with customer demand and new MCC capacity.
2 more points from Accent Microcell's call on capex
Create a free account to keep reading this call
FundraisingQ4 FY26 call
PlannedSee what Accent Microcell said on fundraising — free account, 30 seconds.
Order bookQ4 FY26 call
- Accent Microcell Ltd. stated they have an overall order book for premium products covering at least 3 to 4 months for both export and domestic markets.
- In the context of MNC Indian customers, the approval process is ongoing with expected approvals in the near future, which would likely increase domestic revenue in the next year.
- Orders related to premium product range are active and provide visibility for a few months ahead.
- The company aims to ramp up production phases (Phase 1 and Phase 2) to meet increasing demand reflected in the order books.
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Accent Microcell.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Accent Microcell
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Accent Microcell
Shareholding breakup across reporting periods.
| Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 55.09% | 55.09% | 55.09% | 55.09% | 55.44% | 55.44% | 55.47% | 53.02% | 51.40% |
| FIIs + | 0.03% | 0.02% | 0.01% | 0.01% | 0.00% | 0.29% | 0.58% | 0.91% | 0.72% |
| DIIs + | 1.62% | 1.66% | 2.19% | 2.88% | 3.29% | 3.57% | 3.59% | 3.54% | 2.43% |
| Public + | 43.26% | 43.23% | 42.70% | 42.01% | 41.27% | 40.70% | 40.36% | 42.53% | 45.46% |
| No. of Shareholders | 2,418 | 2,999 | 2,834 | 2,982 | 3,061 | 3,076 | 3,054 | 3,178 | 3,371 |
Financials of Accent Microcell
Quarterly Results
Quarter-by-quarter operating performance
Financials of Accent Microcell
Profit & Loss
Annual income statement trend
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 114 | 131 | 133 | 166 | 197 | 246 | 265 | 349 | 384 |
| Expenses + | 108 | 122 | 122 | 153 | 178 | 206 | 223 | 292 | 310 |
| Operating Profit | 6 | 9 | 11 | 13 | 19 | 39 | 42 | 57 | 74 |
| OPM % | 4.9% | 7% | 8% | 8% | 10% | 16% | 16% | 16% | 19% |
| Other Income + | 6 | 4 | 2 | 2 | 2 | 3 | 6 | 7 | 7 |
| Interest | 3 | 3 | 3 | 3 | 3 | 1 | 0 | 1 | 0 |
| Depreciation | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 |
| Profit before tax | 5 | 6 | 6 | 8 | 15 | 37 | 44 | 58 | 76 |
| Tax % | 24% | 31% | 20% | 22% | 17% | 17% | 24% | 25% | |
| Net Profit + | 4 | 4 | 5 | 6 | 12 | 30 | 33 | 44 | 57 |
| EPS in Rs | 2.46 | 2.84 | 3.27 | 4.01 | 8.26 | 12.57 | 13.78 | 18.28 | 23.72 |
| Dividend Payout % | 0% | 0% | 9% | 18% | 8% | 7% | 6% | 5% |
Financials of Accent Microcell
Balance Sheet
Capital structure and asset base
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 13 | 13 | 21 | 21 | 24 | 24 |
| Reserves | 17 | 21 | 22 | 19 | 37 | 143 | 174 | 252 | 280 |
| Borrowings + | 32 | 30 | 31 | 24 | 23 | 13 | 2 | 1 | 1 |
| Other Liabilities + | 20 | 22 | 23 | 38 | 37 | 28 | 32 | 45 | 41 |
| Total Liabilities | 73 | 77 | 81 | 95 | 111 | 205 | 228 | 322 | 346 |
| Fixed Assets + | 30 | 29 | 30 | 30 | 31 | 29 | 48 | 53 | 56 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 2 | 13 | 102 | 135 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 43 | 48 | 50 | 64 | 79 | 174 | 168 | 167 | 155 |
| Total Assets | 73 | 77 | 81 | 95 | 111 | 205 | 228 | 322 | 346 |
Financials of Accent Microcell
Cash Flows
Operating, investing and financing cash movement
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 6 | 5 | 5 | 15 | 8 | 11 | 25 | 19 |
| Cash from Investing Activity + | -4 | -2 | -6 | -4 | -4 | -82 | -9 | -49 |
| Cash from Financing Activity + | -1 | -2 | -2 | -10 | -4 | 72 | -14 | 36 |
| Net Cash Flow | 1 | 1 | -3 | 1 | -1 | 1 | 2 | 6 |
| Free Cash Flow | 2 | 3 | -0 | 11 | 3 | -2 | -12 | -68 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 120% | 72% | 57% | 127% | 53% | 44% | 85% | 56% |
Financials of Accent Microcell
Ratios
Working capital efficiency and return ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 70 | 60 | 35 | 38 | 56 | 80 | 89 | 95 |
| Inventory Days | 67 | 78 | 128 | 128 | 128 | 83 | 76 | 55 |
| Days Payable | 89 | 80 | 74 | 97 | 106 | 48 | 42 | 33 |
| Cash Conversion Cycle | 48 | 58 | 88 | 68 | 79 | 114 | 124 | 117 |
| Working Capital Days | 19 | 30 | 37 | 16 | 41 | 79 | 101 | 95 |
| ROCE % | 18% | 17% | 19% | 27% | 31% | 24% | 25% |
Guidance history
How Accent Microcell's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q4 FY26 call → | 10–20% | Up 2%+ | Planned | Planned | — |
| Q1 FY26 call → | 10–20% | Flat | Planned | Planned | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
92 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +138.3% | 96% |
| Last 6 months | +49.1% | 89% |
| Last 3 months | +28.2% | 90% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Accent Microcell: 0.4 × 96 + 0.4 × 89 + 0.2 × 90 = 92.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Accent Microcell's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY